Literature DB >> 12679754

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?

Gregory P Gerschutz1, Deepak L Bhatt.   

Abstract

The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study investigated the use of clopidogrel in the treatment of acute coronary syndromes. Clopidogrel treatment led to an impressive 20% relative risk reduction in the composite outcome measure of vascular death, myocardial infarction, and stroke. Increased bleeding and greater requirements for blood transfusions were seen with clopidogrel. The addition of clopidogrel to aspirin represents a major advance in the treatment of acute coronary syndromes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679754     DOI: 10.1067/mhj.2003.180

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

Review 1.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

2.  Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.

Authors:  David Fitchett; John Eikelboom; Stephen Fremes; David Mazer; Steve Singh; Bindu Bittira; Stephanie Brister; John J Graham; Milan Gupta; Keyvan Karkouti; Agnes Lee; Michael Love; Rod McArthur; Mark Peterson; Subodh Verma; Terrence M Yau
Journal:  Can J Cardiol       Date:  2009-12       Impact factor: 5.223

3.  Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction?

Authors:  Essa Hariri; Darleen Lessard; Joel Gore; Jeffrey Rade; Robert Goldberg
Journal:  Cardiovasc Revasc Med       Date:  2019-05-02

4.  Clopidogrel Within Few Hours of Coronary Artery Bypass Grafting Does Significantly Increase the Risk of Bleeding.

Authors:  Emad M Hijazi; Ghassan S Musleh
Journal:  Cardiol Res       Date:  2012-09-20

Review 5.  Dual Antiplatelet Therapy before Coronary Artery Bypass Grafting; a Systematic Review and Meta-Analysis.

Authors:  Roxana Sadeghi; Asrin Babahajian; Arash Sarveazad; Naser Kachoueian; Mansour Bahardoust
Journal:  Arch Acad Emerg Med       Date:  2020-05-31

6.  Dual antiplatelet therapy before coronary artery bypass grafting in patients with myocardial infarction: a prospective cohort study.

Authors:  Roxana Sadeghi; Mohammad Haji Aghajani; Reza Miri; Naser Kachoueian; Amir Nasser Jadbabaei; Mohammad Parsa Mahjoob; Fatemeh Omidi; Mahboobeh Ghazanfarabadi; Arash Sarveazad
Journal:  BMC Surg       Date:  2021-12-31       Impact factor: 2.102

7.  Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.

Authors:  Oskar Angerås; Pål Hasvold; Marcus Thuresson; Anna Deleskog; Oscar ÖBraun
Journal:  Scand Cardiovasc J       Date:  2015-12-11       Impact factor: 1.589

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.